Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine

European Journal of Clinical Pharmacology

Volumn 57, Issue 1, 2001, Pages 31-36

  Giancarlo, G M ^a   Venkatakrishnan, K ^a   Granda, B W ^a   Von Moltke, L L ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C19; CYP2C9; Phenytoin

Indexed keywords

ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; FLURBIPROFEN; MEPHENYTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; SULFAPHENAZOLE; TICLOPIDINE;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENYTOIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFAPHENAZOLE; TICLOPIDINE;

EID: 0035028935     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100268     Document Type: Article

References (33)

1. Co-regulation of phenytoin and tolbutamide metabolism in humans
2. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes
3. Roles of cytochrome P450 2C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite
4. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: Differences in chiral preference of CYP2C9 and CYP2C19
5. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19
6. Ticlopidine inhibits phenytoin clearance
7. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
8. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vitro
9. Xenobiotic metabolizing human cells as tools for pharmacological and toxicological research
10. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
11. Role of cytochrome P450 2C9 and an allelic variant in the 4-hydroxylation of (R)- and (S)-flurbiprofen
12. Studies of flurbiprofen 4-hydroxylation: Additional evidence suggesting the sole involvement of cytochrome P450 2C9
13. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate
14. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
15. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin para-hydroxylation
16. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
17. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism
18. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
19. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
20. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
21. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation
22. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
23. Inhibition of human cytochrome P450 isoforms by non-nucleoside reverse transcriptase inhibitors
24. Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast
25. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
26. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
27. A study of the interaction between omeprazole and phenytoin in epileptic patients
28. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity
29. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
30. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6
31. Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation
32. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: Roles of cytochromes P450 2C9, 2C19, and 3A4
33. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes